Inclusion Criteria:  Adults ≥18 years of age  History of a respiratory tract infection (RTI) for more than one but less than six days including two or more of the following signs and symptoms of an RTI:  • Fever (T ≥ 38.0 C, 100.5 F), cough, sputum production, arthralgia/myalgia, anosmia/ageusia or difficulty breathing.  A nasal or throat swab or nasal wash positive by PCR for SARS-CoV-2. Has given written informed consent to participate in the study. Due to the public health issues related to this viral infection, witnessed informed consent may be obtained remotely.  Exclusion Criteria:  Exclusion Criteria:  Patients likely, in the opinion of the investigator, to require hospitalization within 48 hours of randomization into the study. Concurrent use of non-study antibacterial drug therapy that would have a potential effect on outcome evaluations in patients with an RTI Concurrent use of any other medications for the purpose of treating a viral infection such as influenza antivirals Inability to swallow oral medication in tablet form Patient has severe chronic kidney disease, or is receiving hemodialysis, or peritoneal dialysis or had a renal transplant Patient is known to have severe neutropenia Patients with a known prolongation of the QT interval or are taking medications which could prolong the QT interval Patient is known to be pregnant Patients with a known history of myasthenia gravis Patients with a history of allergy to azithromycin, hydroxychloroquine or chloroquine Patient is considered unlikely to survive the study period or has a rapidly progressive or terminal illness, including septic shock, associated with a high risk of mortality